Pharmacogenomics in Renal Transplantation: Tailoring Tacrolimus for Enhanced Patient Outcomes

Dear Editor, In pharmacogenomics, genetic information is used to understand how individuals respond to different drugs. When a person has a specific gene variant linked to how they react to a drug, doctors can potentially make better treatment decisions by adjusting the dosage or trying a different medication. This is done through methods like analyzing multiple genes or whole-genome single nucleotide polymorphism (SNP). These techniques are now starting to be used at an early stage to aid in finding and determining effective medication use. Overall, when studying how drugs work in people, the major focus is on two main things: figuring out the right amount of a drug needed to reach its target in the body and understanding how well the target cells respond to the drug, as depicted in Figure 1.[1] Renal transplantation stands as a well-founded therapeutic choice for patients with end-stage renal disease. Over recent decades, the efficacy of transplants has markedly advanced, primarily attributed to the adoption of robust immunosuppressive protocols aimed at preventing graft rejection.[2] However, despite these, some recipients may encounter challenges related to inadequate or excessive immunosuppression.Figure 1: Depicted basic drug responses through pharmacogenomics in patients with different genotypesTacrolimus is a common medication used after kidney transplants to lower the risk of rejection. However, it needs careful monitoring because the right dose varies a lot between people. To make sure it works well and does not cause too many side effects, doctors regularly check the levels of tacrolimus in the blood.[3] Pharmacogenomics offers valuable insights into optimizing immunosuppressive therapy in renal transplantation, allowing for personalized treatment approaches that improve outcomes and quality of life for transplant recipients. CYP3A5 genetic variations have been linked to changes in the way tacrolimus is processed within the bodies of renal transplant recipients, impacting its pharmacokinetics. CYP3A5 is a member of the cytochrome P450 superfamily of enzymes, which are primarily involved in the metabolism of various endogenous and exogenous compounds in the body.[4,5] Individuals can exhibit genetic variability in the expression and function of CYP3A5 due to genetic polymorphisms. One of the most studied polymorphisms is a SNP known as CYP3A5*3, which results in decreased expression and activity of the enzyme in individuals carrying this variant.[3] As a result, individuals with different CYP3A5 genotypes may metabolize drugs differently, leading to variations in drug efficacy and toxicity. The variation at position 6986 (A>G) in the CYP3A5 gene leads to changes in how efficiently the CYP3A5 protein processes substances, including tacrolimus. Individuals with CYP3A5 expresser genotypes (A/A *1/*1 and A/G *1/*3) break down tacrolimus faster compared to those with nonexpresser genotypes (G/G *3/*3), impacting tacrolimus concentration in patients. Several studies show that a specific gene variant called CYP3A5*3 (rs776746c.6986A>G) affects the metabolism of tacrolimus. This variation can cause fluctuations in tacrolimus dose after the transplant.[3,5] These fluctuations are linked to different types of the CYP3A5 gene. This can impact the success of the transplant, potentially leading to rejection or early loss of the transplanted organ. People with certain versions of the CYP3A5 gene, labeled as CYP3A5-AA (*1/*1) or AG (*1/*3), typically need higher doses of tacrolimus to maintain the desired levels in their blood compared to those with the GG (*3/*3) version. Conversely, those with the GG (*3/*3) version may need lower doses to avoid potential side effects from the medication.[3,5-7] Understanding the role of CYP3A5 and its genetic variability is essential in personalized medicine, as it can help predict individual responses to drugs and optimize treatment strategies based on a person’s genetic makeup. By understanding the intricate interplay between genetics and drug metabolism, personalized medicine can revolutionize posttransplant care, minimizing adverse reactions, and maximizing therapeutic benefits. This underscores the crucial role of genetic variability assessment in guiding precision medicine approaches, ultimately ensuring the success and longevity of renal transplants. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.